评价药源性心脏毒性生物标志物的研究进展

doi:10.20223/j.cnki.1000-8535.2025.01.007

摘要/Abstract

摘要： 药源性心脏毒性是临床常见的药物不良反应,是药物研发和临床治疗需面临的严峻考验。对药源性心脏毒性的评价是目前研究的重点,基于其机制复杂多样、临床表现不一、影响因素多,早期评价具有困难。生物标志物是评价心脏毒性的重要指标之一,文章总结了目前已经报道的多种心脏毒性标志物及其潜在的生物标志物,希望能从中找到特异性强、敏感性高的标志物,以贡献于药物心脏安全性评价工作。

关键词: 药源性, 心脏毒性, 生物标志物

Abstract: As a common clinical adverse reaction,pharmacogenic cardiotoxicity is a severe challenge for drug development and clinical treatment．The evaluation of pharmacogenic cardiotoxicity is the focus of current research,and early evaluation is difficult with its complex and diverse mechanisms,varying clinical manifestations,and numerous influencing factors．Biomarker is an important index to evaluate cardiotoxicity．This article summarizes a variety of cardiotoxicity biomarkers and other potential biomarkers that have been reported so far,hoping to find biomarkers with strong specificity and high sensitivity,so as to contribute to the evaluation on cardiac safety of drugs．

Key words: pharmacogenic, cardiotoxicity, biomarkers

程昱, 李美凤, 李艳芬, 舒文沁, 文湄伊. 评价药源性心脏毒性生物标志物的研究进展[J]. 广州医药, 2025, 56(1): 48-55.

CHENG Yu, LI Meifeng, LI Yanfen, SHU Wenqin, WEN Meiyi. Research progress in evaluating biomarkers of pharmacogenic cardiotoxicity[J]. Guangzhou Medical Journal, 2025, 56(1): 48-55.

参考文献

[1] 国家药品不良反应监测年度报告(2023年)[J].中国病毒病杂志,2024,14(3):204-210.
[2] 张冰,萨日娜,张晓朦,等.药源性心脏毒性研究进展[J].中国药物警戒,2023,20(8):841-847.
[3] 苏毅馨,朱世杰,薛鹏,等.阿霉素心脏毒性的研究进展[J].临床肿瘤学杂志,2020,25(11):1048-1054.
[4] 潘校琦,阎博华,周杰,等.中药药源性心脏毒性研究进展[J].药学进展,2020,44(10):730-742.
[5] ZHOU J,PENG F,CAO X,et al.Risk compounds,preclinical toxicity evaluation,and potential mechanisms of Chinese materia medica-induced cardiotoxicity[J].Front Pharmacol,2021(12):578796.
[6] 于瑞,李彬,王永霞,等.中药心脏毒性及临床评价方法的思考[J].中草药,2019,50(18):4485-4489.
[7] 谢晓芳,彭成.附子心脏毒效的多维评价和整合分析研究进展[J].世界中医药,2017,12(11):2555-2562.
[8] MAHMOOD S S,RIEDELL P A,FELDMAN S,et al.Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients[J].Eur Heart J,2023,44(22):2029-2042.
[9] 赵得堡,屈中玉,孙星,等.蒽环类药物序贯曲妥珠单抗治疗导致乳腺癌患者心脏毒性的相关危险因素研究[J].广州医药,2023,54(3):105-108.
[10] KHAIRNAR S I,KULKARNI Y A,SINGH K.Cardiotoxicity linked to anticancer agents and cardioprotective strategy[J].Arch Pharm Res,2022,45(10):704-730.
[11] SIMÕES R,SILVA L M,CRUZ A L V M,et al.Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy:A narrative review[J].Biomed Pharmacother,2018(107):989-996.
[12] CARDINALE D,SANDRI M T,MARTINONI A,et al.Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy[J].J Am Coll Cardiol,2000,36(2):517-522.
[13] BRACUN V,ABOUMSALLEM J P,van der MEER P,et al.Cardiac biomarkers in patients with cancer:Considerations,clinical implications,and future avenues[J].Curr Oncol Rep,2020,22(7):67.
[14] 王淑荣,陈小淼,凌霜,等.雷公藤与附子心脏急性毒性的血浆生物标志物的初步探讨[J].时珍国医国药,2016,27(3):759-761.
[15] CLERICO A,CARDINALE D M,ZANINOTTO M,et al.High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy[J].Clin Chem Lab Med,2020,59(3):513-521.
[16] DOVGANYCH N V,KOZHUKHOV S M,SMOLANKA I I,et al.Cardiotoxicity in breast cancer patients:Relationship of hs-troponin t changes and heart function in cancer treatment[J].Probl Radiac Med Radiobiol,2022(27):440-454.
[17] 中国临床肿瘤协会指南工作委员会.中国临床肿瘤协会(CSCO)乳腺癌诊疗指南2024[M].北京.人民卫生出版社,2024:1-150.
[18] TZOLOS E,ADAMSON P D,HALL P S,et al.Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy[J].Clin Oncol(R Coll Radiol),2020,32(5):292-297.
[19] GRELA-WOJEWODA A,PÜSKÜLLÜOĞLU M,SAS-KORCZYŃSKA B,et al.Biomarkers of Trastuzumab-induced cardiac toxicity in HER2- positive breast cancer patient population[J].Cancers(Basel),2022,14(14):3353.
[20] LYON A R,YOUSAF N,BATTISTI N M L,et al.Immune checkpoint inhibitors and cardiovascular toxicity[J].Lancet Oncol,2018,19(9):e447-e458.
[21] 冯群,李晓宇,栾永福,等.附子水提物单次给药对小鼠心脏“量-时-毒”关系研究[J].中国中药杂志,2015,40(5):927-932.
[22] LU X,ZHAO Y,CHEN C,et al.BNP as a marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer[J].Oncol Lett,2019,18(5):4992-5001.
[23] HASAN D,ISMAIL Y,AL TIBI A,et al.Serum biomarkers for chemotherapy cardiotoxicity risk detection of breast cancer patients[J].Asian Pac J Cancer Prev,2021,22(10):3355-3363.
[24] LIANG L,CUI C,LV D,et al.Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor-associated cardiotoxicity[J].ESC Heart Fail,2023,10(3):1907-1918.
[25] NISHIMOTO Y,KATO T,MORIMOTO T,et al.C-reactive protein at discharge and 1-year mortality in hospitalised patients with acute decompensated heart failure:An observational study[J].BMJ Open,2020,10(12):e041068.
[26] 张宝权. 白细胞介素-6在病理性心肌重构中的研究进展[J].中国城乡企业卫生,2023,38(5):42-44.
[27] ASNANI A,SHI X,FARRELL L,et al.Changes in Citric acid cycle and nucleoside metabolism are associated with anthracycline cardiotoxicity in patients with breast cancer[J].J Cardiovasc Transl Res,2020,13(3):349-356.
[28] LI Y,JU L,HOU Z,et al.Screening,verification,and optimization of biomarkers for early prediction of cardiotoxicity based on metabolomics[J].J Proteome Res,2015,14(6):2437-2445.
[29] 王香杰. 精氨酸-NO代谢产物及MPO在蒽环类药物急性心脏毒性中的研究[D].承德:承德医学院,2021.
[30] 陈璐璐,袁祯爽,刘婕,等.基于网络毒理学和代谢组学的青蒿琥酯心脏毒性作用机制研究[J].世界科学技术-中医药现代化,2023(12):25.
[31] ZHANG Y,KENT J W 2ND,LEE A,et al.Fatty acid binding protein 3(fabp3)is associated with insulin,lipids and cardiovascular phenotypes of the metabolic syndrome through epigenetic modifications in a Northern European family population[J].BMC Med Genomics,2013(6):9.
[32] HAN X,ZHANG S,CHEN Z,et al.Cardiac biomarkers of heart failure in chronic kidney disease[J].Clin Chim Acta,2020(510):298-310.
[33] MCCANN C J,GLOVER B M,MENOWN I B,et al.Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T[J].Eur Heart J,2008,29(23):2843-2850.
[34] KELLENS S,VERBRUGGE F H,VANMECHELEN M,et al.Point-of-care heart-type fatty acid binding protein versus high-sensitivity troponin T testing in emergency patients at high risk for acute coronary syndrome[J].Eur Heart J Acute Cardiovasc Care,2016,5(2):177-184.
[35] YUAN M,ZANG L,XU A,et al.Dynamic changes of serum heart type-fatty acid binding protein in cancer patients treated with immune checkpoint inhibitors[J].Front Pharmacol,2021(12):748677.
[36] TURAN T,AGAC M T,AYKAN A Ç,et al.Usefulness of heart-type fatty acid-binding protein and myocardial performance index for early detection of 5-fluorouracil cardiotoxicity[J].Angiology,2017,68(1):52-58.
[37] SERRANO J M,MATA R,GONZÁLEZ I,et al.Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients:Incidence and predictors[J].Int J Cardiol,2023(382):52-59.
[38] SAWALHA K,NORGARD N B,DREES B M,et al.Growth differentiation factor 15(GDF-15),a new biomarker in heart failure management[J].Curr Heart Fail Rep,2023,20(4):287-299.
[39] KEMPF T,von HAEHLING S,PETER T,et al.Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure[J].J Am Coll Cardiol,2007,50(11):1054-1060.
[40] 王碗. 辛伐他汀对蒽环类药物性心脏毒性的保护意义及相关机制研究[D].承德:承德医学院,2022.
[41] ARKOUMANI M,PAPADOPOULOU-MARKETOU N,NICOLAIDES N C,et al.The clinical impact of growth differentiation factor-15 in heart disease:A 2019 update[J].Crit Rev Clin Lab Sci,2020,57(2):114-125.
[42] RABITZSCH G,MAIR J,LECHLEITNER P,et al.Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury[J].Clin Chem,1995,41(7):966-978.
[43] GHIMIRE A,GIRI S,KHANAL N,et al.Diagnostic accuracy of glycogen phosphorylase BB for myocardial infarction:A systematic review and meta-analysis[J].J Clin Lab Anal,2022,36(5):e24368.
[44] 杨柳. 从细胞凋亡途径探讨石菖蒲心脏毒性作用及机制[D].广州:广州中医药大学,2018.
[45] HORACEK J M,JEBAVY L,VASATOVA M,et al.Glycogen phosphorylase BB as a potential marker of cardiac toxicity in patients treated with anthracyclines for acute leukemia[J].Bratisl Lek Listy,2013,114(12):708-710.
[46] DI J Y,ZHANG Z X,XIN S J.Glycogen phosphorylase isoenzyme bb,myoglobin and BNP in ANT-induced cardiotoxicity[J].Open Life Sci,2018(13):561-568.
[47] MAISEL A S,DI SOMMA S.Do we need another heart failure biomarker:focus on soluble suppression of tumorigenicity 2(sST2).Eur Heart J,2017 ,38(30):2325-2333.
[48] 段奇. sST-2对接受阿霉素化疗乳腺癌患者心功能的预测价值[D].郑州:郑州大学,2020.
[49] CHEN C,LI J,ROSSI L,et al.Prognostic role of serum soluble ST2 of advanced breast cancer patients:A retrospective cohort study[J].Transl Cancer Res,2023,12(8):2128-2137.
[50] NETTERSHEIM F S,SCHLÜTER J D,KREUZBERG W,et al.Myeloperoxidase is a critical mediator of anthracycline-induced cardiomyopathy[J].Basic Res Cardiol,2023,118(1):36.
[51] PUTT M,HAHN V S,JANUZZI J L,et al.Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin,taxanes,and trastuzumab[J].Clin Chem,2015 ,61(9):1164-1172.
[52] KY B,PUTT M,SAWAYA H,et al.Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin,taxanes,and trastuzumab[J].J Am Coll Cardiol,2014,63(8):809-816.
[53] WU Y,GAO D,XUE J,et al.Galectin-3 and myeloperoxidase may monitor cancer-therapy-related cardiotoxicity?A systematic review and meta-analysis[J].Biomolecules,2022,12(12):1788.
[54] BROWN C,MANTZARIS M,NICOLAOU E,et al.A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research[J].Cardiooncology,2022,8(1):16.
[55] RIGAUD V O,FERREIRA L R,AYUB-FERREIRA S M,et al.Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients[J].Oncotarget,2017,8(4):6994-7002.
[56] 葛运炫. 乌头类生物碱经CYP代谢对心肌细胞毒性和hERG通道的影响[D].合肥:安徽医科大学,2019.
[57] 董增祥,赵鑫,李宝馨.As2O3诱发获得性LQTS的机制及药物逆转作用[C]// 中国药理学会第十三届全国化疗药理学术研讨会会议论文集.沈阳,2016:58.
[58] LIU J,LI D,LUO H,et al.Circular RNAs:The star molecules in cancer[J].Mol Aspects Med,2019(70):141-152.
[59] CLARK M B,JOHNSTON R L,INOSTROZA-PONTA M,et al.Genome-wide analysis of long noncoding RNA stability[J].Genome Res,2012,22(5):885-898.